Turkey Grappling With Rising Asthma Burden
This article was originally published in PharmAsia News
Executive Summary
A new report on asthma in Turkey reveals the real economic cost of the disease for the country. Prepared by four academicians, it highlights the high rate of patients whose disease remains uncontrolled and are not receiving any regular treatment, and notes the role of drug treatment.
You may also be interested in...
Turkish Medtechs Up In Arms Over Partial Write-Off Of $2Bn+ Hospital Debt
Unpaid hospital debts have been hitting the Turkish medical sector for some time, but a government plan to repay less than the full amount owed has angered industry.
Turkey’s $2.6Bn Hospital Medtech Debts Create Problems On Top Of COVID-19
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
COVID-19 Pushes Ongoing Concerns of Turkish Medtech Industry Down The Agenda
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Need a specific report? 1000+ reports available
Buy Reports